We got onto the buzz about “transparent aluminum” as a result of a Tweet from whence the image above came. This Tweet was posted by [Jo Pitesky], a Science Systems Engineer at the Jet ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

This move has been supported by a wide range of stocks, including AbbVie. Data by YCharts Investors have been buying AbbVie with both hands, as the company has proven it can move beyond the Humira ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its ...

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 – jumping from levels of $90 then to around $195 now – vs. an increase of about 50% for the S&P 500 over this ...

AbbVie's Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven's Nurtec The top-selling CGRP is Pfizer’s Nurtec, which rang up sales of $928 million last year.

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...

If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the First Trust Morningstar Dividend Leaders ETF (FDL), a passively managed exchange ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...